Compare WhiteOak Capital Pharma and Healthcare Fund vs SBI Healthcare Opportunities Fund
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.37 | 1.93 |
NAV | ₹13.56 | ₹420.93 |
Fund Started | 16 Jan 2024 | 04 Jun 1999 |
Fund Size | ₹508.73 Cr | ₹3989.42 Cr |
Exit Load | Exit load of 1%, if redeemed within 1 months. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.37
1.93
NAV
₹13.56
₹420.93
Fund Started
16 Jan 2024
04 Jun 1999
Fund Size
₹508.73 Cr
₹3989.42 Cr
Exit Load
Exit load of 1%, if redeemed within 1 months.
Exit load of 0.50% if redeemed within 15 days
1 Year | 4.29% | 0.20% |
3 Year | - | 23.54% |
5 Year | - | 15.54% |
1 Year
4.29%
0.20%
3 Year
-
23.54%
5 Year
-
15.54%
Equity | 98.58% | 96.59% |
Cash | -4.95% | 3.34% |
Equity
98.58%
96.59%
Cash
-4.95%
3.34%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.91% |
JB Chemicals & Pharmaceuticals Ltd. | 8.38% |
Max Healthcare Institute Ltd. | 6.90% |
Laurus Labs Ltd. | 5.44% |
Fortis Healthcare Ltd. | 5.25% |
Lupin Ltd. | 4.79% |
Divi's Laboratories Ltd. | 4.50% |
Cipla Ltd. | 3.90% |
Alkem Laboratories Ltd. | 2.76% |
Neuland Laboratories Ltd. | 2.49% |
Sun Pharmaceutical Industries Ltd. | 11.64% |
Divi's Laboratories Ltd. | 7.05% |
Max Healthcare Institute Ltd. | 5.24% |
Lupin Ltd. | 4.44% |
Laurus Labs Ltd. | 3.89% |
Torrent Pharmaceuticals Ltd. | 3.86% |
Acutaas Chemicals Ltd. | 3.85% |
Cipla Ltd. | 3.79% |
Lonza Group Ag | 3.63% |
Biocon Ltd. | 3.16% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 16 Jan 2024 | 04 Jun 1999 |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
16 Jan 2024
04 Jun 1999